The global Extracorporeal Membrane Oxygenation (ECMO) market was valued at USD 267.1 million in 2019 and is expected to reach USD 371.8 million by the year 2027, at a CAGR of 4.2%. Extracorporeal membrane oxygenation is a treatment provided for COVID-19, cardiac and respiratory diseases. Increasing the prevalence of target diseases (such as COVID-19, cardiovascular diseases and respiratory diseases), technological advancements, and increasing extracorporeal membrane oxygenation centers across the globe are some of the factors driving the market growth. It is estimated that in the U.S., approximately 1,055,000 individuals will have coronary diseases, including 720,000 new and 335,000 recurrent coronary events. The number of artificial respiration via the help of the device in a developed nation such as the U.S. from the past decade is constantly on rise. With rising technological innovations improved survival rate with extracorporeal membrane oxygenation is another major factor that supports the spread of the adoption of extracorporeal membrane oxygenation in case of medical emergencies such as COVID-19 cases. In South Korea it has been observed that the inpatient with Extracorporeal membrane oxygenation therapy for respiratory failure had improved survival rate from 30.8% to 35.9%.
Top Companies Profiled in the Report Include:
Getinge Group (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), XENIOS AG (Germany), Terumo Corporation (Japan), MicroPort Scientific Corporation (China), NIPRO Corporation (Japan), OriGen Biomedical, Inc. (U.S.), ALung Technologies, Inc. (Germany), and EUROSETS S.r.l. (Italy).
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2465
Market Overview:
The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness. Companies operating in the industry have invested heavily in clinical trials and research studies to develop medications to cater to the growing unmet clinical demand on a global level. Implementation of cutting-edge technology in healthcare sector and increasing investment in research and development have contributed significantly to revenue growth of the market in the recent past. In addition, availability of favorable health insurance and reimbursement policies have also positively impacted the healthcare sector with more and more individuals opting to get treatment at hospital and clinical facilities. Rapid development of novel drugs and pharmaceuticals, increasing incidence of lifestyle and chronic diseases, establishment of state-of-the-art healthcare facilities, and rising availability of over-the-counter medications have significantly contributed to the revenue growth of the market.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2465
The report has gather vital information about recent mergers and acquisitions, joint ventures, collaborations, partnerships, brand promotions, R&D activities, and government and corporate deals, among others through extensive primary and secondary research. The report also offers detailed analysis of each competitor along with their financial standing, global market position, product portfolio, manufacturing and production capacity, and business expansion plans.
The report offers a comprehensive overview of the regional bifurcation of the market with respect to market share, market size, revenue growth, import/export, production and consumption patterns, macro and micro economic growth factors, regulatory framework, investment and funding opportunities, and presence of key players in each region including North America, Asia Pacific, Latin America, Europe, and Middle East & Africa. The report offers a country-wise analysis to further discuss the revenue growth and lucrative growth opportunities for the Extracorporeal Membrane Oxygenation (ECMO) market in these key regions.
Country-wise regional analysis covers:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
To know more about the report @ https://www.reportsanddata.com/press-release/global-extracorporeal-membrane-oxygenation-ecmo-market
Additionally, the report consists a detailed analysis of the segmentation of the Extracorporeal Membrane Oxygenation (ECMO) market based on product types and end-use/application offered in the Extracorporeal Membrane Oxygenation (ECMO) market.
Type Outlook (Revenue, USD Million; 2017-2027)
- Venovenous ECMO
- Venoarterial ECMO
- Arteriovenous ECMO
Component Outlook (Revenue, USD Million; 2017-2027)
- Pumps
- Cannula
- Oxygenators
- Gas Blender
- Heat Exchanger
- Pressure Monitor
- Bladder Reservoir
- Controller
- Gas Cylinder
- Others
Application Outlook (Revenue, USD Million; 2017-2027)
- Congenital Diaphragmatic Hernia (CDH)
- Birth Defects of the Heart
- Meconium Aspiration Syndrome (MAS)
- Severe Pneumonia
- Severe Air Leak Problems
- Severe High Blood Pressure in the Arteries of the Lungs (PPHN)
- Others
End Use Outlook (Revenue, USD Million; 2017-2027)
- Pediatric
- Adult
Thank you for reading our report. For customization inquiry or further information, please connect with us and we will ensure you get the report that meets your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Reports and Data has recently added a new comprehensive research report on the global Coextruded Medical Tubes market with key details about market share, market size, market revenue growth, CAGR, and other vital statistical data for the forecast period of 2021-2028.
The report is furnished with valuable insights gathered from extensive primary and secondary research and further validated from industry experts and professionals.
Extrusion, VistaMed, ACE, and Precision Extrusion Inc.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/605Market Overview: The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness.
Implementation of cutting-edge technology in healthcare sector and increasing investment in research and development have contributed significantly to revenue growth of the market in the recent past.
In addition, availability of favorable health insurance and reimbursement policies have also positively impacted the healthcare sector with more and more individuals opting to get treatment at hospital and clinical facilities.
Rapid development of novel drugs and pharmaceuticals, increasing incidence of lifestyle and chronic diseases, establishment of state-of-the-art healthcare facilities, and rising availability of over-the-counter medications have significantly contributed to the revenue growth of the market.
The global circulating tumor cells market size is expected to reach USD 26.45 Billion by 2028 according to a new study by Polaris Market Research.
The report “Circulating Tumor Cells Market Share, Size, Trends, Industry Analysis Report, By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis); By Application (Clinical/Liquid Biopsy, Research); By Product; By Specimen; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Circulating tumor cells obtained via liquid biopsies are safer, cheaper, and less invasive than other surgical biopsies as liquid biopsies are considered a valuable tool in cancer diagnosis, before and after the onset of disease.
Though circulating tumor cells technology is still under research phase but used for the prognosis of several cancer forms including, breast, melanoma, lung, colon, pancreas, and glioblastoma.
Owing to the advantages and non-invasiveness of CTCs, the market companies and concerned academic institutions are undertaking several strategic initiatives to expand of CTCs in clinical facilities.
Companies operating in the market of circulating tumor cells such as Greiner Bio-One; BioFluidica, QIAGEN; Bio-Techne Corporation; Rarecells Diagnostics, ScreenCell, Menarini Silicon Biosystems; Fluxion Biosciences, Sysmex Corporation; Miltenyi Biotec, and Biocept, Inc.
Global Advanced Cardiovascular Life Support Market - OverviewAdvanced cardiovascular life support is also referred as advanced cardiac life support is a set of clinical interventions for the emergency treatment of stroke and other life-threatening medical emergencies.
However, limited number of trained personnel has restrained of the growth of market.Further The prevalence of cardiovascular diseases across the globe is continuously increasing owing to rising geriatric population, increasing diabetic population, and changing the lifestyle of the people.
Currently, major companies are dropping down the cost of their cardiovascular devices across the globe, especially, developing region like Asia Pacific, where individuals or users cannot afford the high cost of the products.
On the other hand, the small and medium-size companies are focusing to grab local market with its low cost, which forces the major companies to reduce the price of their products.
According to the Centers for Medicare & Medicaid Services, in 2015, the U.S. healthcare spending is likely to increase 5.8% reaching USD 3.2 trillion.
Western Europe continues to see a need to save money on healthcare because of a slight drop in financial growth and obstinate economic pressure.
The Active Implantable Medical Devices Market is expected to witness significant growth in the coming years.
The growing aging population, increasing prevalence of cardiovascular and neurological diseases, investments and funds to develop technologically advanced products, expanded applications of neurostimulators, and favorable reimbursement scenario for ENT procedures in developed countries are some of the factors driving the growth of this market.The Global Active Implantable Medical Devices Market witnessed healthy growth expected to grow at a CAGR of 7.8%, to reach $ 26.75 billionLucrative opportunities in emerging markets and the development of subcutaneous implantable cardioverter defibrillators offer significant growth opportunities in this market.
Increasing market consolidation and the development of innovative, easy-to-use implantable cardiovascular products with increased longevity are the major trends for this market.Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102063992Active Implantable Medical Devices Market segmentation:On the basis of product, the market is segmented into implantable cardioverter defibrillators, implantable cardiac pacemakers, implantable heart monitors/insertable loop recorders, ventricular assist devices, neurostimulators, and implantable hearing devices.
The implantable cardioverter defibrillators segment accounted for the largest share of the implantable and life-sustaining devices market in 2016, owing to the increasing incidence of cardiovascular diseases, development of technologically advanced devices, and increasing demand for these devices in emerging countries.Based on region, the active implantable medical devices market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.The active implantable medical devices market is highly consolidated in nature where the prominent players are accounting for the major share.
To expand their geographic presence and garner higher shares in this market, major players are continuously focusing on product launches; mergers and acquisitions; agreements, partnerships, and collaborations; and expansions.Geographic Analysis: # Further breakdown of the Rest of Asia-Pacific market into, Australia, New Zealand, and others# Further breakdown of the Rest of Latin America active implantable medical devices market into Brazil, Argentina, and MexicoThe Major Players Operating in the Active Implantable Medical Devices Market:Medtronic plc (Ireland), Abbott Laboratories (U.S.), and Boston Scientific Corporation (U.S.) held the major share of the implantable cardiovascular and neurostimulators devices market.
Whereas, Cochlear Limited (Australia), MED-EL (Austria), Sonova Holding AG (Switzerland), and William Demant Holding A/S (Denmark) held the major share of the implantable hearing devices market.Other major players operating in the implantable cardiovascular and neurostimulators devices market are BIOTRONIK SE & Co. KG (Germany) and LivaNova PLC (U.K.).
Active implantable medical devices market size is set to reach $28.8 billion by 2023, growing at a CAGR of 8.0% between 2017-2023.
Technological advancements, increasing prevalence of cardiovascular diseases, increasing healthcare expenditures and rising research and development activities are the major factors driving the growth of the market.The R investments for the development of novel and innovative active implantable medical devices are increasing due to increased demand for effective implantable medical devices.
Moreover, the currently available devices require surgical implantation and replacement surgeries after every few years.
The technologically advanced implantable medical devices facilitate non-invasive procedures for the safe and effective treatment of drug-resistant neurological disorders.
Many companies in the active implantable medical devices market such as Medtronic Inc., Boston Scientific Corporation, LivaNova plc, William Demant Holding AG and Cochlear Ltd. are actively involved in the development of new and advanced active implantable devices.Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/active-implantable-medical-devices-market/report-sampleThe Asia-Pacific active implantable medical devices market is expected to grow at the fastest rate in the forecast period as compared to other regions, mainly due to growing aging population in various countries, such as India and China.
Moreover, the substantially larger base of the aging population in these Asian countries, is expected to drive the growth of the active implantable medical device market in the region.
Autoinjectors are easy-to-handle and cost-effective medical devices that can be used by patients, caregivers, and even untrained personnel to deliver a dose of a particular drug.
Autoinjectors are used by patients to manage autoimmune diseases and chronic diseases.
They are used for a wide range of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors marketRheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues.
It causes joints to swell and can result in pain, stiffness, and progressive loss of function.
According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia.What Drives the Market?1.
Growing prevalence of targeted therapies2.
